Skip to main content
. 2021 Dec 13;12:7233. doi: 10.1038/s41467-021-27493-0

Fig. 2. Selected ionizable lipids under clinical development for COVID-19 mRNA vaccines and other RNA therapeutics.

Fig. 2

Ionizable lipids used in on-going clinical trials have not been publicly disclosed, so one of the possible structures (Acuitas A946, Arcturus Lipid 2,2 (8,8) 4C CH347, Genevant CL148 and LP0149,50) is shown, respectively. i.v. intravenous, i.m. intramuscular.